Topic

Articles

The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers. 

Gilead to Acquire Immunomedics for $21 Billion

The companies have signed a definitive agreement to acquire a majority stake of PCI Pharma Services.

Kohlberg and Mubadala to Acquire Majority Stake in PCI Pharma Services

The facility offers office, production, sampling, and warehouse space and delivers products to all major global markets.

TriRx to Acquire Merck’s MSD Sante Animale Manufacturing Facility 

The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

Nestlé Health Science to Acquire Aimmune Therapeutics for $2.6 Billion

The transaction will give Ionis access to Akcea's pipeline and commercial products, as well as its cash on hand of approximately $390 million.

Ionis to Acquire Akcea Common Stock for $500 Million

AbCellera’s recent acquisition of the OrthoMab bispecific platform is expected to accelerate antibody product development.

AbCellera’s Acquisition of OrthoMab Bispecific Platform Propels Antibody Development

Müller + Müller will become part of DWK upon closing in September 2020 and will continue to function under the same name and management. 

DWK Life Sciences to Acquire Müller + Müller

The deal is expected to close during the second half of 2020.

J&J to Acquire Momenta Pharmaceuticals for $6.5 billion

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase (BTK) inhibitors to add to its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi to Acquire Principia Biopharma for $3.68 Billion

The companies will work to establish an operational footprint across North America and Europe that will offer customers supply chain assurance for a combined portfolio of leading solutions.

Mergers and Acquisitions